Bezafibrate improves markers of [[combined hyperlipidemia]], effectively reducing LDL and triglycerides and improving HDL levels.<ref>{{cite journal | title = Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study | journal = Circulation | volume = 102 | issue = 1 | pages = 21–7 | year = 2000 | pmid = 10880410 | doi=10.1161/01.cir.102.1.21}}</ref> The main effect on cardiovascular morbidity is in patients with the [[metabolic syndrome]], the features of which are attenuated by bezafibrate.<ref>{{cite journal | last1 = Tenenbaum | first1 = A | last2 = Motro | first2 = M | last3 = Fisman | first3 = EZ | last4 = Tanne | first4 = D | last5 = Boyko | first5 = V | last6 = Behar | first6 = S | title = Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome | journal = Archives of Internal Medicine | volume = 165 | issue = 10 | pages = 1154–60 | year = 2005 | pmid = 15911729 | doi = 10.1001/archinte.165.10.1154 }}</ref> Studies show that in patients with impaired glucose tolerance, bezafibrate may delay progress to diabetes,<ref>{{cite journal | last1 = Tenenbaum | first1 = A | last2 = Motro | first2 = M | last3 = Fisman | first3 = EZ | last4 = Schwammenthal | first4 = E | last5 = Adler | first5 = Y | last6 = Goldenberg | first6 = I | last7 = Leor | first7 = J | last8 = Boyko | first8 = V | last9 = Mandelzweig | first9 = L | last10 = Behar | first10 = S | title = Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease | journal = Circulation | volume = 109 | issue = 18 | pages = 2197–202 | year = 2004 | pmid = 15123532 | doi = 10.1161/01.CIR.0000126824.12785.B6 | display-authors = 8 }}</ref> and in those with [[insulin resistance]] it slowed progress in the [[homeostatic model assessment|HOMA]] severity marker.<ref>{{cite journal | last1 = Tenenbaum | first1 = A | last2 = Fisman | first2 = EZ | last3 = Boyko | first3 = V | last4 = Benderly | first4 = M | last5 = Tanne | first5 = D | last6 = Haim | first6 = M | last7 = Matas | first7 = Z | last8 = Motro | first8 = M | last9 = Behar | first9 = S | title = Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate | journal = Archives of Internal Medicine | volume = 166 | issue = 7 | pages = 737–41 | year = 2006 | pmid = 16606809 | doi = 10.1001/archinte.166.7.737  }}</ref> In addition, a prospective observational study of dyslipidemic patients with diabetes or hyperglycemia showed that bezafibrate significantly reduces haemoglobin A1c (HbA1c) concentration as a function of baseline HbA1c levels, regardless of concurrent use of antidiabetic drugs.<ref>{{cite journal | url = http://www.cardiab.com/content/11/1/29, | pmid = 22439599 | doi=10.1186/1475-2840-11-29 | volume=11 | title=Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study | pmc=3342914 | issue=1 | year=2012 | journal=Cardiovasc Diabetol | page=29 | last1 = Teramoto | first1 = T | last2 = Shirai | first2 = K | last3 = Daida | first3 = H | last4 = Yamada | first4 = N}}</ref>

 
==Side-effects==
